The Alzheimer’s debate may not seem positive, but AC Immune’s CEO promises it’s been a breakthrough yearnews2021-12-21T00:53:26+00:00December 21st, 2021|FierceBiotech|
2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anywaynews2021-12-20T20:15:34+00:00December 20th, 2021|FierceBiotech|
No data, no problem. Senti will go public in $296M SPAC deal before hitting the clinicnews2021-12-20T18:06:14+00:00December 20th, 2021|FierceBiotech|
Aptose finally ditches APTO-253 after 3-year clinical hold, phase 1 dudnews2021-12-20T16:59:18+00:00December 20th, 2021|FierceBiotech|
This is just the Spark: Roche’s new gene therapy manufacturing center leaves space for growthnews2021-12-20T15:50:53+00:00December 20th, 2021|FierceBiotech|
Roche adds to Genentech’s ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics’ assetnews2021-12-20T15:12:56+00:00December 20th, 2021|FierceBiotech|
Novartis brings on first TIGIT drug in massive billion-dollar biobucks deal with BeiGenenews2021-12-20T14:37:59+00:00December 20th, 2021|FierceBiotech|
Forbion arms biotech to stop sudden cardiac death, leading $35M round to fund phase 2 trial of Armgo’s pipeline-in-a-productnews2021-12-20T11:11:25+00:00December 20th, 2021|FierceBiotech|
Novartis suffers shock setback as Xolair successor fails phase 3news2021-12-20T08:07:50+00:00December 20th, 2021|FierceBiotech|
2022 forecast: Pharma has the tools. Will clinical trials be less white in next year?news2021-12-17T19:00:09+00:00December 17th, 2021|FierceBiotech|
